# CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease

> **NCT03618641** · PHASE2 · COMPLETED · sponsor: **Diwakar Davar** · enrollment: 34 (actual)

## Conditions studied

- Melanoma
- Lymph Node Cancer

## Interventions

- **DRUG:** CMP-001
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT03618641
- **Lead sponsor:** Diwakar Davar
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-08
- **Primary completion:** 2020-08-20
- **Final completion:** 2023-12-31
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2025-05-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03618641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03618641, "CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03618641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*